Clinical Trial Update: NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)

View source ↗

Summary

A non-interventional study (NIS) evaluating the effectiveness and safety of durvalumab and olaparib in patients with endometrial cancer (DUOLife).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Endometrial Cancer | Status: RECRUITING